TNGX Tango Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
• • Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises

Risk Factors

• • Newly added risk: Ongoing U.S. government shutdown since Sept 30, 2025 impacting FDA, SEC operations and potentially delaying regulatory reviews
• • Most materially updated risk: Executive Orders 14273 and 14297 direct aggressive federal drug pricing policies, potentially affecting pricing, approvals, and market access

What are the latest TNGX SEC filings in 2026?

Tango Therapeutics, Inc. (TNGX) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 15, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TNGX file its most recent 10-K annual report?

Tango Therapeutics, Inc. (TNGX) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TNGX 10-Q quarterly reports?

Tango Therapeutics, Inc. (TNGX)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every TNGX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TNGX filed recently?

Tango Therapeutics, Inc. (TNGX)'s most recent 8-K was filed on April 15, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TNGX insider trading activity (Form 4)?

SignalX aggregates every TNGX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TNGX file with the SEC?

Tango Therapeutics, Inc. (TNGX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TNGX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Tango Therapeutics, Inc. (TNGX).

What is TNGX's SEC CIK number?

Tango Therapeutics, Inc. (TNGX)'s SEC CIK (Central Index Key) number is 1819133. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1819133 to look up all TNGX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TNGX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Tango Therapeutics, Inc. (TNGX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.